Google_______________

HIV Infection Is Linked to Lung Cancer Independent of Tobacco Smoking

By Liz Highleyman

In the July 1, 2007 issue of Clinical Infectious Diseases, researchers from Johns Hopkins University presented results of a study of lung cancer rates in people with HIV. Past findings -- including those from a recent meta-analysis -- indicate that HIV positive people are at higher risk for lung cancer. However, it is not known to what extent this increased risk is due to smoking, which has been reported as more common among HIV positive compared with HIV negative people.

The investigators assessed data from the AIDS Link to the Intravenous Experience (ALIVE) study, a prospective observation cohort of 2086 injection drug users in Baltimore followed since 1988. About one-quarter were HIV positive at baseline, and 334 more seroconverted during follow-up. At study entry, about 90% of participants smoked, with 45% consuming 20 or more cigarettes (1 pack) per day and 10% consuming at least 40 cigarettes. Smoking, and the amount smoked, were similar in the HIV positive and HIV negative groups.

Lung cancer deaths were identified through linkage with the National Death Index. Cox proportional hazards regression was used to examine the effect of HIV infection on lung cancer risk, controlling for smoking status, drug use, and clinical variables.

Results

·  Among 2086 study participants observed for a total of 19,835 person-years, 27 lung cancer deaths were identified.

·  14 of these deaths were among HIV positive persons.

·  After adjusting for potential confounding factors including smoking, HIV positive participants had a 3.4-fold increased risk of death due to lung cancer.

·  All but 1 (96%) of the patients with lung cancer were smokers, smoking a mean of 1.2 packs per day.

·  Lung cancer mortality increased since the advent of effective combination antiretroviral therapy compared with the pre-HAART era (mortality rate ratio 4.7).

·  After adjusting for age, sex, smoking status, and calendar period, HIV infection was associated with a significantly increased risk of lung cancer (hazard ratio 3.6).

·  Pre-existing lung disease, particularly non-infectious diseases and asthma, displayed trends for increased lung cancer risk.

·   Use of illegal drugs was not associated with increased lung cancer risk.

·   Among HIV positive persons, smoking remained the major risk factor for lung cancer, with the risk increasing by 70%-80% per additional daily pack of cigarettes.

·   CD4 cell count and HIV load were not strongly associated with increased lung cancer risk, and trends for increased risk related to use of HAART were not significant.

Conclusion

In conclusion, the authors wrote, “HIV infection is associated with significantly increased risk for developing lung cancer, independent of smoking status.”

07/13/07

Reference
GD Kirk, C Merle, P O’Driscoll, and others.
HIV infection is associated with an increased risk of lung cancer, independent of smoking. Clinical Infectious Diseases 45(1): 103-110. July 1, 2007.


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Fortovase (saquinavir soft gel)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritronavir)
Lexiva
(Fosamprenavir)
Norvir (ritonavir)
Prezista
(darunavir)
Reyataz (atazanavir)
Viracept
(nelfinavir)

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (AZT+ 3TC)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Hivid (zalcitabine; ddC)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (Tenofovir / Emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor (delavirdine)

Sustiva (efavirenz)
Viramune (nevirapine)

Entry Inhibitors
Fuzeon (enfuvirtide; T-20)

Fixed-dose Combinations
Atripla
(efavirenz + emtricitabine + tenofovir)
Combivir
(retrovir + lamivudine)

Trizivir
(abacavir + zidovudine + lamivudine)
Truvada
(tenofovir + emtricitabine)